Clinical disclaimer: This article is for informational and educational purposes only. It does not constitute medical advice and is not a substitute for a consultation with a qualified clinician. Never stop, interrupt, or adjust medication without clinical supervision.

Key Points

  • A new BMJ Medicine study found that in adults with type 2 diabetes, interrupting or discontinuing GLP-1 medication was associated with loss of cardiovascular benefit — not merely weight regain
  • A gap of around six months was associated with measurable erosion of benefit
  • Restarting after interruption did not appear to fully restore the benefit of uninterrupted treatment
  • The population was US veterans with type 2 diabetes — this does not map directly onto every private obesity patient in the UK
  • The paper does not prove that every patient must remain on a GLP-1 indefinitely — it makes the case for careful, planned stopping rather than casual discontinuation

The short answer

If you are searching for information about stopping GLP-1 drugs, this is what the new BMJ Medicine paper shows: in adults with type 2 diabetes, interrupting or discontinuing GLP-1 receptor agonists was associated with loss of cardiovascular benefit, with risk rising as time off treatment lengthened. [1]

The practical takeaways: this is not only about weight regain; brief interruption may matter more than many assumed; and the paper does not mean every person on a private weight-loss prescription must stay on a GLP-1 forever. What most coverage gets wrong is lazy absolutism. The important part is not the headline — it is how to interpret it without turning one observational paper into doctrine.

What the new BMJ Medicine paper studied

The paper, published in BMJ Medicine in March 2026, examined real-world patterns of GLP-1 receptor agonist use and discontinuation in adults with type 2 diabetes using a target trial emulation design. [1] The cohort was drawn from the US Veterans Affairs healthcare system — more than 333,000 veterans followed for up to three years, comparing GLP-1 users with people prescribed sulfonylureas. [1,2]

Three important things that description tells you: First, this was not a randomised trial. Second, this was a type 2 diabetes population, not a general private weight-loss population. Third, the paper tracked different patterns — continued use, discontinuation, and interruption followed by resumption. [1,2]

What the study found

Compared with continued use, discontinuation and interruption were associated with worse cardiovascular outcomes. [1] The key numbers:

  • Continuous use over three years: 18% reduction in major adverse cardiovascular events vs sulfonylurea users [2]
  • Stopping for less than 18 months: no significant risk reduction by end of study [2]
  • A gap of around six months: measurable erosion of benefit [2]
  • One to two years off treatment: 14% to 22% higher risk of major cardiovascular events vs staying on treatment [2]
  • Restarting after interruption: less benefit than uninterrupted use [2]

This is consistent with the STEP 4 withdrawal data and the SELECT trial, which showed semaglutide reducing major cardiovascular events by 20% in high-risk patients with overweight or obesity and established cardiovascular disease. [3,4]

Planning to stop Wegovy, Ozempic or Mounjaro? A GLP-1 Exit Strategy Review builds a plan around your cardiovascular risk, glycaemic status, appetite management and what replaces the drug. Clinician-led, not generic.

View the GLP-1 Exit Strategy →

What most articles miss

This is not a proof-of-eternity paper

The study does not prove every patient should remain on a GLP-1 indefinitely. It shows that in a large, high-risk, real-world type 2 diabetes population, benefit appears tied to continuity. Medicine becomes stupid when association is mistaken for theology.

Interruption and discontinuation are different problems

A patient stopping because of unbearable nausea is not the same as a patient stopping because the pharmacy cannot supply the drug. Neither is the same as a patient who has reached a plateau and wants a structured off-ramp. If side effects are driving the problem, a deprescribing review looks at whether dose, drug, or timing needs adjusting — not simply whether to stop.

The population matters

US veterans with type 2 diabetes. A 52-year-old with type 2 diabetes, central adiposity, hypertension and prior vascular disease is much closer to this paper's target than a 34-year-old private patient who used tirzepatide for obesity and wants to come off after a 15 kg loss. The first should read this with real caution. The second with interest, but not panic.

Restarting may not fully restore lost ground

Restarting after interruption did not appear to restore the same degree of cardiovascular benefit as uninterrupted use. [2] That makes casual stop-start use look less benign than social media suggests.

Three overlapping GLP-1 conversations

Type 2 diabetes treatment. Obesity treatment. Cardiovascular risk reduction. NICE's April 2026 recommendation on semaglutide for adults with established cardiovascular disease and BMI ≥27 kg/m² makes the third category much harder to ignore. [6,7] Once a drug class becomes part of cardiovascular prevention, the threshold for casual discontinuation changes.

What this means for private GLP-1 users

For the patient with type 2 diabetes, established cardiovascular risk, or previous vascular disease: be cautious about stopping casually. [1,2]

For the patient using a GLP-1 privately for obesity without diabetes: the lesson is not "never stop." It is: do not confuse weight-loss success on treatment with proof that the underlying physiology has been solved.

A good GLP-1 exit strategy asks at least six questions: Why are you stopping? What happens to appetite when the drug is withdrawn? What is your glycaemic risk? What is your cardiovascular risk? What body-composition change was achieved? What physiological structure will replace the drug?

For patients whose overall medication picture is complex, an Independent Medication Review produces a full written assessment — not just the GLP-1.

A practical timeline after stopping

Phase by phase after stopping GLP-1 treatment

First 2 weeks
Some people feel very little. Others notice appetite return and less early satiety. This is often the most deceptive phase. Absence of immediate weight rebound does not mean the off-ramp is going well. Record appetite changes, not just weight. Tighten meal structure before hunger fully reasserts itself.
Weeks 3–6
Hunger may be more obvious, food thoughts more frequent. In people with diabetes, glycaemia may begin to worsen. Assess whether the stop was appropriate or forced by circumstance. A Clinical Data Review at this stage — bloods, weight trend, glucose data — gives a clear picture.
Beyond 6 weeks
The question is no longer "have I stopped?" but "what equilibrium am I drifting towards?" If appetite, weight, blood pressure, glycaemia or lipid control are deteriorating, the experiment has yielded its answer. [1,2,5] Re-evaluate cardiovascular risk, not just appearance.

When to seek urgent help

Seek urgent medical advice if, after stopping a GLP-1 drug, you develop: chest pain or shortness of breath; new focal neurological symptoms; severe dehydration from vomiting; signs of marked hyperglycaemia (excessive thirst, polyuria, vomiting, drowsiness or confusion); or severe abdominal pain especially if persistent.

When to involve your clinician

Involve your clinician promptly if: you have type 2 diabetes; you have prior heart attack, stroke, or peripheral arterial disease; the medication was stopped because of side effects and you are considering restarting; your appetite, weight, or glycaemic control is worsening within weeks of stopping; you are moving in and out of treatment because of availability or cost; or you want to come off but do not have a maintenance plan.

The real clinical question

The wrong question is: Can I stop my GLP-1?

The better question is: What problem was the GLP-1 suppressing, and what happens when that suppression is removed?

The serious conclusion from this paper is that stopping is not a neutral administrative event. In higher-risk patients, it may mean surrendering cardiovascular protection that took time to build and little time to lose. [1,2]

Starting is easy. Coming off well is the hard part.

If you are planning to stop, or already have: a GLP-1 Exit Strategy Review builds a plan around your specific situation. Clinical Data Review is available for patients who want bloods, weight trend and metabolic markers reviewed in full.

Book or enquire →

FAQ

What happens when you stop GLP-1 drugs?
Usually the first issues are return of appetite, reduced satiety, and drift in eating behaviour. Over time, many people regain weight, and cardiometabolic markers may worsen again. [2,5]
Do heart benefits disappear when you stop semaglutide?
In this new BMJ Medicine study of adults with type 2 diabetes, discontinuation or interruption was associated with loss of cardiovascular benefit compared with continued use. [1,2] That does not prove identical effects in every lower-risk obesity patient, but it is a serious warning in higher-risk groups.
Can you take a break from Ozempic or Mounjaro and then restart?
You can in practice, but the new study suggests interruption is not benign. Restarting appeared to restore only part of the benefit seen with uninterrupted treatment. [2]
Is weight regain after stopping semaglutide common?
Yes. In the STEP 1 extension, participants regained around two-thirds of prior weight loss within a year of stopping semaglutide 2.4 mg. [5] See also the full guide to coming off Wegovy and Ozempic.
Does this new paper apply to private weight-loss patients?
Only partly. The study population was adults with type 2 diabetes in the US Veterans Affairs system, so it is more directly relevant to higher-risk diabetes patients than to every private obesity patient. [1,2]
Is GLP-1 treatment meant to be lifelong?
Not automatically. The answer depends on indication, risk, response, tolerability and what physiological structure exists once the drug is withdrawn. [1-7]
Should I stop GLP-1 medication suddenly?
That depends on why you are stopping. If you have diabetes, cardiovascular disease, severe side effects, or rapidly worsening glycaemia, involve your clinician rather than improvise. [1,2,6]
What is the biggest mistake people make when stopping GLP-1 drugs?
They assume that because the scales have improved, the underlying physiology has been solved. Often it has merely been pharmacologically contained.
What should a proper GLP-1 exit strategy include?
A proper exit strategy should cover indication, appetite rebound, glycaemic risk, cardiovascular risk, body-composition trend, side-effect history, and the plan that replaces the drug rather than merely removes it.

References

  1. BMJ Medicine. Target trial emulation of GLP-1 receptor agonist discontinuation and cardiovascular outcomes in adults with type 2 diabetes. BMJ Medicine, March 2026.
  2. Washington University School of Medicine. Stopping GLP-1 drugs can quickly erase cardiovascular benefits. News release, March 2026.
  3. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. N Engl J Med. 2023;389:2221-2232. (SELECT)
  4. SELECT trial primary publication. NEJM 2023.
  5. STEP 4 / STEP 1 extension. Semaglutide withdrawal and weight regain.
  6. NICE. Semaglutide injection to help prevent heart attacks and strokes. April 2026.
  7. NICE. Semaglutide for preventing cardiovascular events. In development GID-TA11544.